GSK launches antihistamine

GlaxoSmithKline Pharmaceuticals (GSK) launched a non-sedative antihistamine syrup Histaban (loratadine), a prescription medication for allergic conditions. The syrup intended for paediatric use, is manufactured at the Glaxo Wellcome Ceylon plant in Sri Lanka.

“Loratadine is a second-generation antihistamine, and the availability of a locally developed product from GSK will be welcomed by the medical fraternity,” said Managing Director, GSK Pharmaceuticals in Sri Lanka, Stuart Chapman. “GSK's highest global standards have been adhered to in the manufacture, to ensure quality, safety and efficacy.”

“Histaban is a long-acting antihistamine and there is no restriction in a patient's activities since it is non-sedative,” a spokesman for the company said.